Trump Announces Largest Drop in Prescription Drug Prices in US History

President Trump has declared a historic victory for American patients, announcing the 17th and final agreement with a major pharmaceutical manufacturer to secure Most-Favored-Nation (MFN) pricing. The deal with Regeneron completes a coalition of 17 leading manufacturers—representing 86% of the branded drug market—who have agreed to rebalance international pricing so that Americans no longer pay more than the lowest price available in other developed nations. A central piece of the announcement is the expansion of TrumpRx.gov, a government-backed marketplace where patients can access massive discounts directly. Highlights include the price of Ozempic falling from over $1,000 to an average of $350, and fertility medication Cetrotide plunging from $316 to just $22.50. Additionally, the Regeneron deal secures $10 billion in domestic manufacturing investment and provides the new gene therapy Otarmeni at no cost to eligible patients, with the President vowing that "the era of foreign nations freeriding on American innovation is officially over." #TrumpRx #DrugPrices #MFNPricing #Regeneron #BreakingNews #HealthcareReform #AmericaFirst #Ozempic #BigPharma #AffordableMeds